铂类抗肿瘤药物研究进展  

Development of platinum antineoplastic agents

作　　者：叶瑞萍[1] 杨扬(综述)[1] 陈振东(审校)[1] 

机构地区：[1]安徽医科大学第一附属医院肿瘤内科,合肥230022

出　　处：《国际肿瘤学杂志》2008年第9期674-677,共4页Journal of International Oncology

摘　　要：奈达铂、奥沙利铂等新型铂类抗肿瘤药物在临床上广泛应用，其具有抗癌谱广、活性强、不良反应低、与顺铂无交叉耐药性等特点。此外，尚处于临床研究中的亲脂性铂配合物、多核铂配合物等新型铂类化合物，也显示出提高疗效、降低不良反应的优势。目前的研究主要是通过改良顺铂、卡铂的结构和探索结构全新的铂类化合物，以达到提高患者生活质量、延长生存时问的目的。铂类化合物在细胞毒药物中仍然占有重要的地位和良好的应用前景。Nedaplatin and oxaliplatin are widely used in clinic as new antineoplastic agents against a broad spectrum of solid tumors, which arc characterized by broader anticancer spectrum, higher activity and less toxicity, especially no cross resistance with cisplatin. In addition, the lipophilic platinum compound, the muhinuclear platinum compound and others are being still clinically tested, which also show the advantages of high efficacy and low toxicity. Current researches are mainly focus on reforming the structure of cisplatin and carboplatin, and exploring platinum compounds with totally new structure to improve quality of life and prolonging survival time of patients. Platinum compounds still have exceedingly vital position and satisfactory application perspective in cytotoxic drugs.

关 键 词：抗肿瘤药 铂化合物 肿瘤 

分 类 号：R9[医药卫生—药学]